ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001441

A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse

Identifieur interne : 001441 ( PascalFrancis/Corpus ); précédent : 001440; suivant : 001442

A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse

Auteurs : J. A. Aguirre ; A. Cintra ; J. Hillion ; J. A. Narvaez ; A. Jansson ; T. Antonelli ; L. Ferraro ; F. A. Rambert ; K. Fuxe

Source :

Neuroscience letters [ 0304-3940 ] ; 1999.

RBID : Pascal:99-0547776

Descripteurs français

Pascal (Inist)
- Lésion, Locus niger, Modafinil, Neuroprotecteur, Stéréologie, Dopamine, Parkinson maladie, Modèle animal, Mâle, MPTP.

English descriptors

KwdEn :
- Animal model, Dopamine, Lesion, Locus niger, Male, Modafinil, Neuroprotective agent, Parkinson disease, Stereology.

Abstract

The effect of an acute administration of the vigilance-promoting drug modafinil ((±)(diphenyl-methyl)-sulfinyl-2 acetamide ; Modiodal) on the nigrostriatal dopamine system was studied after damage induced by MPTP (1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by means of immunohistochemistry for tyrosine hydroxylase (TH) and a stereological method. MPTP (40 mg/kg) reduced from 24 380 ± 902 to 13 501 ± 522 and from 37 868 ± 3300 to 20 568 ± 1270, respectively, the number of TH immunoreactive (IR) and non-TH IR nigral neurons. Co-administration of Modafinil restored to normal the number of these neuronal populations. MPTP treatment induced also a reduction in the volume of TH IR neurons, which was counteracted by Modafinil administration. The data provide morphological evidence, based on unbiased stereological analysis, for a potential neuroprotective role of Modafinil, not only in dopaminergic neurons, but also with a similar magnitude in the non-DA nerve cell population of the substantia nigra after MPTP lesion. These results suggest that Modafinil has a neuroprotective role in the substantia nigra via a still undefined mechanism in which a crucial role of DA uptake blockade should be excluded. Modafinil may therefore have a therapeutic potential in neurodegenerative processes such as those occurring in Parkinson's disease.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0304-3940`
A02	`01`			`@0 NELED5`
A03		`1`		`@0 Neurosci. lett.`
A05				`@2 275`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse`
A11	`01`	`1`		`@1 AGUIRRE (J. A.)`
A11	`02`	`1`		`@1 CINTRA (A.)`
A11	`03`	`1`		`@1 HILLION (J.)`
A11	`04`	`1`		`@1 NARVAEZ (J. A.)`
A11	`05`	`1`		`@1 JANSSON (A.)`
A11	`06`	`1`		`@1 ANTONELLI (T.)`
A11	`07`	`1`		`@1 FERRARO (L.)`
A11	`08`	`1`		`@1 RAMBERT (F. A.)`
A11	`09`	`1`		`@1 FUXE (K.)`
A14	`01`			`@1 Department of Physiology, School of Medicine @2 29080, Malaga @3 ESP @Z 1 aut. @Z 4 aut.`
A14	`02`			`@1 Department of Neuroscience, Karolinska Institutet @2 17177, Solna @3 SWE @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 9 aut.`
A14	`03`			`@1 Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara @2 Ferrara @3 ITA @Z 6 aut. @Z 7 aut.`
A14	`04`			`@1 Laboratoire L. Lafon @2 Maisons-Alfort @3 FRA @Z 8 aut.`
A20				`@1 215-218`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17240 @5 354000080503700160`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 99-0547776`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neuroscience letters`
A66	`01`			`@0 IRL`
C01	`01`		`ENG`	@0 The effect of an acute administration of the vigilance-promoting drug modafinil ((±)(diphenyl-methyl)-sulfinyl-2 acetamide ; Modiodal) on the nigrostriatal dopamine system was studied after damage induced by MPTP (1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by means of immunohistochemistry for tyrosine hydroxylase (TH) and a stereological method. MPTP (40 mg/kg) reduced from 24 380 ± 902 to 13 501 ± 522 and from 37 868 ± 3300 to 20 568 ± 1270, respectively, the number of TH immunoreactive (IR) and non-TH IR nigral neurons. Co-administration of Modafinil restored to normal the number of these neuronal populations. MPTP treatment induced also a reduction in the volume of TH IR neurons, which was counteracted by Modafinil administration. The data provide morphological evidence, based on unbiased stereological analysis, for a potential neuroprotective role of Modafinil, not only in dopaminergic neurons, but also with a similar magnitude in the non-DA nerve cell population of the substantia nigra after MPTP lesion. These results suggest that Modafinil has a neuroprotective role in the substantia nigra via a still undefined mechanism in which a crucial role of DA uptake blockade should be excluded. Modafinil may therefore have a therapeutic potential in neurodegenerative processes such as those occurring in Parkinson's disease.
C02	`01`	`X`		`@0 002B02B10`
C03	`01`	`X`	`FRE`	`@0 Lésion @5 01`
C03	`01`	`X`	`ENG`	`@0 Lesion @5 01`
C03	`01`	`X`	`SPA`	`@0 Lesión @5 01`
C03	`02`	`X`	`FRE`	`@0 Locus niger @5 02`
C03	`02`	`X`	`ENG`	`@0 Locus niger @5 02`
C03	`02`	`X`	`SPA`	`@0 Locus níger @5 02`
C03	`03`	`X`	`FRE`	`@0 Modafinil @2 NK @2 FR @5 03`
C03	`03`	`X`	`ENG`	`@0 Modafinil @2 NK @2 FR @5 03`
C03	`03`	`X`	`SPA`	`@0 Modafinilo @2 NK @2 FR @5 03`
C03	`04`	`X`	`FRE`	`@0 Neuroprotecteur @5 04`
C03	`04`	`X`	`ENG`	`@0 Neuroprotective agent @5 04`
C03	`04`	`X`	`SPA`	`@0 Neuroprotector @5 04`
C03	`05`	`X`	`FRE`	`@0 Stéréologie @5 05`
C03	`05`	`X`	`ENG`	`@0 Stereology @5 05`
C03	`05`	`X`	`SPA`	`@0 Estereología @5 05`
C03	`06`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 06`
C03	`06`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 06`
C03	`06`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 06`
C03	`07`	`X`	`FRE`	`@0 Parkinson maladie @5 09`
C03	`07`	`X`	`ENG`	`@0 Parkinson disease @5 09`
C03	`07`	`X`	`SPA`	`@0 Parkinson enfermedad @5 09`
C03	`08`	`X`	`FRE`	`@0 Modèle animal @5 14`
C03	`08`	`X`	`ENG`	`@0 Animal model @5 14`
C03	`08`	`X`	`SPA`	`@0 Modelo animal @5 14`
C03	`09`	`X`	`FRE`	`@0 Mâle @5 54`
C03	`09`	`X`	`ENG`	`@0 Male @5 54`
C03	`09`	`X`	`SPA`	`@0 Macho @5 54`
C03	`10`	`X`	`FRE`	`@0 MPTP @4 INC @5 78`
C07	`01`	`X`	`FRE`	`@0 Encéphale @5 23`
C07	`01`	`X`	`ENG`	`@0 Brain (vertebrata) @5 23`
C07	`01`	`X`	`SPA`	`@0 Encéfalo @5 23`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central @5 24`
C07	`02`	`X`	`ENG`	`@0 Central nervous system @5 24`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso central @5 24`
C07	`03`	`X`	`FRE`	`@0 Neurotransmetteur @5 35`
C07	`03`	`X`	`ENG`	`@0 Neurotransmitter @5 35`
C07	`03`	`X`	`SPA`	`@0 Neurotransmisor @5 35`
C07	`04`	`X`	`FRE`	`@0 Catécholamine @5 36`
C07	`04`	`X`	`ENG`	`@0 Catecholamine @5 36`
C07	`04`	`X`	`SPA`	`@0 Catecolamina @5 36`
C07	`05`	`X`	`FRE`	`@0 Système nerveux pathologie @5 38`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 38`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 38`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 39`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 39`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 39`
C07	`07`	`X`	`FRE`	`@0 Encéphale pathologie @5 40`
C07	`07`	`X`	`ENG`	`@0 Cerebral disorder @5 40`
C07	`07`	`X`	`SPA`	`@0 Encéfalo patología @5 40`
C07	`08`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 41`
C07	`08`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 41`
C07	`08`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 41`
C07	`09`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`09`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`09`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
N21				`@1 355`

Format Inist (serveur)

NO :	PASCAL 99-0547776 INIST
ET :	A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse
AU :	AGUIRRE (J. A.); CINTRA (A.); HILLION (J.); NARVAEZ (J. A.); JANSSON (A.); ANTONELLI (T.); FERRARO (L.); RAMBERT (F. A.); FUXE (K.)
AF :	Department of Physiology, School of Medicine/29080, Malaga/Espagne (1 aut., 4 aut.); Department of Neuroscience, Karolinska Institutet/17177, Solna/Suède (2 aut., 3 aut., 5 aut., 9 aut.); Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara/Ferrara/Italie (6 aut., 7 aut.); Laboratoire L. Lafon/Maisons-Alfort/France (8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neuroscience letters; ISSN 0304-3940; Coden NELED5; Irlande; Da. 1999; Vol. 275; No. 3; Pp. 215-218; Bibl. 17 ref.
LA :	Anglais
EA :	The effect of an acute administration of the vigilance-promoting drug modafinil ((±)(diphenyl-methyl)-sulfinyl-2 acetamide ; Modiodal) on the nigrostriatal dopamine system was studied after damage induced by MPTP (1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by means of immunohistochemistry for tyrosine hydroxylase (TH) and a stereological method. MPTP (40 mg/kg) reduced from 24 380 ± 902 to 13 501 ± 522 and from 37 868 ± 3300 to 20 568 ± 1270, respectively, the number of TH immunoreactive (IR) and non-TH IR nigral neurons. Co-administration of Modafinil restored to normal the number of these neuronal populations. MPTP treatment induced also a reduction in the volume of TH IR neurons, which was counteracted by Modafinil administration. The data provide morphological evidence, based on unbiased stereological analysis, for a potential neuroprotective role of Modafinil, not only in dopaminergic neurons, but also with a similar magnitude in the non-DA nerve cell population of the substantia nigra after MPTP lesion. These results suggest that Modafinil has a neuroprotective role in the substantia nigra via a still undefined mechanism in which a crucial role of DA uptake blockade should be excluded. Modafinil may therefore have a therapeutic potential in neurodegenerative processes such as those occurring in Parkinson's disease.
CC :	002B02B10
FD :	Lésion; Locus niger; Modafinil; Neuroprotecteur; Stéréologie; Dopamine; Parkinson maladie; Modèle animal; Mâle; MPTP
FG :	Encéphale; Système nerveux central; Neurotransmetteur; Catécholamine; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Lesion; Locus niger; Modafinil; Neuroprotective agent; Stereology; Dopamine; Parkinson disease; Animal model; Male
EG :	Brain (vertebrata); Central nervous system; Neurotransmitter; Catecholamine; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD :	Lesión; Locus níger; Modafinilo; Neuroprotector; Estereología; Dopamina; Parkinson enfermedad; Modelo animal; Macho
LO :	INIST-17240.354000080503700160
ID :	99-0547776

Links to Exploration step

Pascal:99-0547776

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse</title>
<author><name sortKey="Aguirre, J A" sort="Aguirre, J A" uniqKey="Aguirre J" first="J. A." last="Aguirre">J. A. Aguirre</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Physiology, School of Medicine</s1>
<s2>29080, Malaga</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cintra, A" sort="Cintra, A" uniqKey="Cintra A" first="A." last="Cintra">A. Cintra</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neuroscience, Karolinska Institutet</s1>
<s2>17177, Solna</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hillion, J" sort="Hillion, J" uniqKey="Hillion J" first="J." last="Hillion">J. Hillion</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neuroscience, Karolinska Institutet</s1>
<s2>17177, Solna</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Narvaez, J A" sort="Narvaez, J A" uniqKey="Narvaez J" first="J. A." last="Narvaez">J. A. Narvaez</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Physiology, School of Medicine</s1>
<s2>29080, Malaga</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jansson, A" sort="Jansson, A" uniqKey="Jansson A" first="A." last="Jansson">A. Jansson</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neuroscience, Karolinska Institutet</s1>
<s2>17177, Solna</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Antonelli, T" sort="Antonelli, T" uniqKey="Antonelli T" first="T." last="Antonelli">T. Antonelli</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara</s1>
<s2>Ferrara</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ferraro, L" sort="Ferraro, L" uniqKey="Ferraro L" first="L." last="Ferraro">L. Ferraro</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara</s1>
<s2>Ferrara</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rambert, F A" sort="Rambert, F A" uniqKey="Rambert F" first="F. A." last="Rambert">F. A. Rambert</name>
<affiliation><inist:fA14 i1="04"><s1>Laboratoire L. Lafon</s1>
<s2>Maisons-Alfort</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fuxe, K" sort="Fuxe, K" uniqKey="Fuxe K" first="K." last="Fuxe">K. Fuxe</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neuroscience, Karolinska Institutet</s1>
<s2>17177, Solna</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0547776</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0547776 INIST</idno>
<idno type="RBID">Pascal:99-0547776</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001441</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse</title>
<author><name sortKey="Aguirre, J A" sort="Aguirre, J A" uniqKey="Aguirre J" first="J. A." last="Aguirre">J. A. Aguirre</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Physiology, School of Medicine</s1>
<s2>29080, Malaga</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cintra, A" sort="Cintra, A" uniqKey="Cintra A" first="A." last="Cintra">A. Cintra</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neuroscience, Karolinska Institutet</s1>
<s2>17177, Solna</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hillion, J" sort="Hillion, J" uniqKey="Hillion J" first="J." last="Hillion">J. Hillion</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neuroscience, Karolinska Institutet</s1>
<s2>17177, Solna</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Narvaez, J A" sort="Narvaez, J A" uniqKey="Narvaez J" first="J. A." last="Narvaez">J. A. Narvaez</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Physiology, School of Medicine</s1>
<s2>29080, Malaga</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jansson, A" sort="Jansson, A" uniqKey="Jansson A" first="A." last="Jansson">A. Jansson</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neuroscience, Karolinska Institutet</s1>
<s2>17177, Solna</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Antonelli, T" sort="Antonelli, T" uniqKey="Antonelli T" first="T." last="Antonelli">T. Antonelli</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara</s1>
<s2>Ferrara</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ferraro, L" sort="Ferraro, L" uniqKey="Ferraro L" first="L." last="Ferraro">L. Ferraro</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara</s1>
<s2>Ferrara</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rambert, F A" sort="Rambert, F A" uniqKey="Rambert F" first="F. A." last="Rambert">F. A. Rambert</name>
<affiliation><inist:fA14 i1="04"><s1>Laboratoire L. Lafon</s1>
<s2>Maisons-Alfort</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fuxe, K" sort="Fuxe, K" uniqKey="Fuxe K" first="K." last="Fuxe">K. Fuxe</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neuroscience, Karolinska Institutet</s1>
<s2>17177, Solna</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroscience letters</title>
<title level="j" type="abbreviated">Neurosci. lett.</title>
<idno type="ISSN">0304-3940</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroscience letters</title>
<title level="j" type="abbreviated">Neurosci. lett.</title>
<idno type="ISSN">0304-3940</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal model</term>
<term>Dopamine</term>
<term>Lesion</term>
<term>Locus niger</term>
<term>Male</term>
<term>Modafinil</term>
<term>Neuroprotective agent</term>
<term>Parkinson disease</term>
<term>Stereology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lésion</term>
<term>Locus niger</term>
<term>Modafinil</term>
<term>Neuroprotecteur</term>
<term>Stéréologie</term>
<term>Dopamine</term>
<term>Parkinson maladie</term>
<term>Modèle animal</term>
<term>Mâle</term>
<term>MPTP</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The effect of an acute administration of the vigilance-promoting drug modafinil ((±)(diphenyl-methyl)-sulfinyl-2 acetamide ; Modiodal) on the nigrostriatal dopamine system was studied after damage induced by MPTP (1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by means of immunohistochemistry for tyrosine hydroxylase (TH) and a stereological method. MPTP (40 mg/kg) reduced from 24 380 ± 902 to 13 501 ± 522 and from 37 868 ± 3300 to 20 568 ± 1270, respectively, the number of TH immunoreactive (IR) and non-TH IR nigral neurons. Co-administration of Modafinil restored to normal the number of these neuronal populations. MPTP treatment induced also a reduction in the volume of TH IR neurons, which was counteracted by Modafinil administration. The data provide morphological evidence, based on unbiased stereological analysis, for a potential neuroprotective role of Modafinil, not only in dopaminergic neurons, but also with a similar magnitude in the non-DA nerve cell population of the substantia nigra after MPTP lesion. These results suggest that Modafinil has a neuroprotective role in the substantia nigra via a still undefined mechanism in which a crucial role of DA uptake blockade should be excluded. Modafinil may therefore have a therapeutic potential in neurodegenerative processes such as those occurring in Parkinson's disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0304-3940</s0>
</fA01>
<fA02 i1="01"><s0>NELED5</s0>
</fA02>
<fA03 i2="1"><s0>Neurosci. lett.</s0>
</fA03>
<fA05><s2>275</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>AGUIRRE (J. A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CINTRA (A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HILLION (J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>NARVAEZ (J. A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>JANSSON (A.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ANTONELLI (T.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>FERRARO (L.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>RAMBERT (F. A.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>FUXE (K.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Physiology, School of Medicine</s1>
<s2>29080, Malaga</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neuroscience, Karolinska Institutet</s1>
<s2>17177, Solna</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara</s1>
<s2>Ferrara</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Laboratoire L. Lafon</s1>
<s2>Maisons-Alfort</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>215-218</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17240</s2>
<s5>354000080503700160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0547776</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuroscience letters</s0>
</fA64>
<fA66 i1="01"><s0>IRL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The effect of an acute administration of the vigilance-promoting drug modafinil ((±)(diphenyl-methyl)-sulfinyl-2 acetamide ; Modiodal) on the nigrostriatal dopamine system was studied after damage induced by MPTP (1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by means of immunohistochemistry for tyrosine hydroxylase (TH) and a stereological method. MPTP (40 mg/kg) reduced from 24 380 ± 902 to 13 501 ± 522 and from 37 868 ± 3300 to 20 568 ± 1270, respectively, the number of TH immunoreactive (IR) and non-TH IR nigral neurons. Co-administration of Modafinil restored to normal the number of these neuronal populations. MPTP treatment induced also a reduction in the volume of TH IR neurons, which was counteracted by Modafinil administration. The data provide morphological evidence, based on unbiased stereological analysis, for a potential neuroprotective role of Modafinil, not only in dopaminergic neurons, but also with a similar magnitude in the non-DA nerve cell population of the substantia nigra after MPTP lesion. These results suggest that Modafinil has a neuroprotective role in the substantia nigra via a still undefined mechanism in which a crucial role of DA uptake blockade should be excluded. Modafinil may therefore have a therapeutic potential in neurodegenerative processes such as those occurring in Parkinson's disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lésion</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lesion</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Lesión</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Locus niger</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Locus niger</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Locus níger</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Modafinil</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Modafinil</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Modafinilo</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Neuroprotecteur</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Neuroprotective agent</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Neuroprotector</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Stéréologie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Stereology</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estereología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Modèle animal</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Animal model</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Modelo animal</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Mâle</s0>
<s5>54</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Male</s0>
<s5>54</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Macho</s0>
<s5>54</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>MPTP</s0>
<s4>INC</s4>
<s5>78</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>23</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>23</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>23</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>24</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>24</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>24</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>35</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>35</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>35</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>36</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>36</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>36</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fN21><s1>355</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0547776 INIST</NO>
<ET>A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse</ET>
<AU>AGUIRRE (J. A.); CINTRA (A.); HILLION (J.); NARVAEZ (J. A.); JANSSON (A.); ANTONELLI (T.); FERRARO (L.); RAMBERT (F. A.); FUXE (K.)</AU>
<AF>Department of Physiology, School of Medicine/29080, Malaga/Espagne (1 aut., 4 aut.); Department of Neuroscience, Karolinska Institutet/17177, Solna/Suède (2 aut., 3 aut., 5 aut., 9 aut.); Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara/Ferrara/Italie (6 aut., 7 aut.); Laboratoire L. Lafon/Maisons-Alfort/France (8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neuroscience letters; ISSN 0304-3940; Coden NELED5; Irlande; Da. 1999; Vol. 275; No. 3; Pp. 215-218; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>The effect of an acute administration of the vigilance-promoting drug modafinil ((±)(diphenyl-methyl)-sulfinyl-2 acetamide ; Modiodal) on the nigrostriatal dopamine system was studied after damage induced by MPTP (1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by means of immunohistochemistry for tyrosine hydroxylase (TH) and a stereological method. MPTP (40 mg/kg) reduced from 24 380 ± 902 to 13 501 ± 522 and from 37 868 ± 3300 to 20 568 ± 1270, respectively, the number of TH immunoreactive (IR) and non-TH IR nigral neurons. Co-administration of Modafinil restored to normal the number of these neuronal populations. MPTP treatment induced also a reduction in the volume of TH IR neurons, which was counteracted by Modafinil administration. The data provide morphological evidence, based on unbiased stereological analysis, for a potential neuroprotective role of Modafinil, not only in dopaminergic neurons, but also with a similar magnitude in the non-DA nerve cell population of the substantia nigra after MPTP lesion. These results suggest that Modafinil has a neuroprotective role in the substantia nigra via a still undefined mechanism in which a crucial role of DA uptake blockade should be excluded. Modafinil may therefore have a therapeutic potential in neurodegenerative processes such as those occurring in Parkinson's disease.</EA>
<CC>002B02B10</CC>
<FD>Lésion; Locus niger; Modafinil; Neuroprotecteur; Stéréologie; Dopamine; Parkinson maladie; Modèle animal; Mâle; MPTP</FD>
<FG>Encéphale; Système nerveux central; Neurotransmetteur; Catécholamine; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Lesion; Locus niger; Modafinil; Neuroprotective agent; Stereology; Dopamine; Parkinson disease; Animal model; Male</ED>
<EG>Brain (vertebrata); Central nervous system; Neurotransmitter; Catecholamine; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Lesión; Locus níger; Modafinilo; Neuroprotector; Estereología; Dopamina; Parkinson enfermedad; Modelo animal; Macho</SD>
<LO>INIST-17240.354000080503700160</LO>
<ID>99-0547776</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001441 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001441 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:99-0547776
   |texte=   A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse

A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri